External Beam Partial Breast Irradiation and MSK 19-300 Alliance Trial

This online course is a highlight from the 2021 live virtual symposium which was hosted by the Miami Cancer Institute. The symposium brought together a distinguished faculty to focus on the medical management of common and important challenges facing healthcare professionals who care for women with cancer.  

Learn more about the Womens’ Cancer Symposium here.

In this course, Erin Gillespie, M.D., will discuss External Beam Partial Breast Irradiation. 

Target Audience

Breast Surgeons, General Surgeons, Reconstructive Surgeons, Obstetricians and Gynecologists, Oncologists,  Physiatrist, Radiation Oncologists, Pathologists, Geneticists, Radiologists, General Practitioners and all other interested healthcare professionals.

Learning Objectives

  • Review available prospective randomized trial evidence supporting safety and efficacy of external beam PBI.
  • Identify and treat eligible patients on an ongoing prospective trial in the MSK Cancer Alliance testing ultra-short external beam PBI.
Additional information
  • Spencer, K., Jones, C. M., Girdler, R., Roe, C., Sharpe, M., Lawton, S., ... & Morris, E. (2021). The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. The Lancet Oncology, 22(3), 309-320.
  • Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., ... & Polgár, C. (2016). Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. The Lancet, 387(10015), 229-238.
  • Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., ... & Thompson, A. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048-1060.
  • Vicini, F. A., Cecchini, R. S., White, J. R., Arthur, D. W., Julian, T. B., Rabinovitch, R. A., ... & Wolmark, N. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. The Lancet, 394(10215), 2155-2164.
  • Whelan, T. J., Julian, J. A., Berrang, T. S., Kim, D. H., Germain, I., Nichol, A. M., ... & El-Sayed, S. (2019). External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. The Lancet, 394(10215), 2165-2172.
Course Summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Course opens: 
Course expires: 

Erin Gillespie, M.D.
Assistant Attending Radiation Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Erin Gillespie, M.D., faculty for this educational activity, is the Co-founder for eContour.org, a free educational website funded by grants for research and education and has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Symposium Directors:
John P. Diaz, M.D., FACOG, has disclosed that he is a member of the speakers’ bureau for AstraZeneca and Merck. 

Gladys L. Giron, M.D., FACS,  has disclosed that that her spouse is a consultant for Stryker. 

Nicholas C. Lambrou, M.D., FACOG,  has disclosed that he is a consultant for Intuitive, Ethicon and Johnson & Johnson. 

Starr K. Mautner, M.D., FACS, has no relevant financial relationship to disclose with ineligible companies.*

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.  

*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.